The Rasch-built Pompe-specific Activity (R-PAct) scale

Neuromuscular Disorders

Volumn 23, Issue 3, 2013, Pages 256-264

  van der Beek, N A M E ^a   Hagemans, M L C ^a   van der Ploeg, A T ^a   van Doorn, P A ^a   Merkies, I S J ^a,b,c  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Department of Orthopaedic Surgery   (Netherlands)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Acid glucosidase; Disability measure; Patient reported outcome measures; Pompe disease; Rasch analysis

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; DAILY LIFE ACTIVITY; DISABILITY; FEMALE; GLYCOGEN STORAGE DISEASE TYPE 2; HUMAN; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PSYCHOLOGICAL ASPECT; PSYCHOMETRY; QUESTIONNAIRE; REPRODUCIBILITY; SEVERITY OF ILLNESS INDEX; SOCIAL BEHAVIOR; TREATMENT OUTCOME; VALIDATION STUDY; VERY ELDERLY;

ACTIVITIES OF DAILY LIVING; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DISABILITY EVALUATION; FEMALE; GLYCOGEN STORAGE DISEASE TYPE II; HUMANS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PSYCHOMETRICS; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; SEVERITY OF ILLNESS INDEX; SOCIAL BEHAVIOR; TREATMENT OUTCOME;

MLCS; MLOWN;

EID: 85027929715     PISSN: 09608966     EISSN: 18732364     Source Type: Journal    
DOI: 10.1016/j.nmd.2012.10.024     Document Type: Article

References (40)

1. van der Ploeg, A.T., Reuser, A.J., Pompe's disease. Lancet 372 (2008), 1342–1353.
2. Kishnani, P.S., Hwu, W.L., Mandel, H., Nicolino, M., Yong, F., Corzo, D., A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. J Pediatr 148 (2006), 671–676.
3. van den Hout, H.M., Hop, W., van Diggelen, O.P., et al. The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature. Pediatrics 112 (2003), 332–340.
4. Engel, A.G., Gomez, M.R., Seybold, M.E., Lambert, E.H., The spectrum and diagnosis of acid maltase deficiency. Neurology 23 (1973), 95–106.
5. Winkel, L.P., Hagemans, M.L., van Doorn, P.A., et al. The natural course of non-classic Pompe's disease; a review of 225 published cases. J Neurol 252 (2005), 875–884.
6. Hagemans, M.L., Winkel, L.P., Hop, W.C., Reuser, A.J., van Doorn, P.A., van der Ploeg, A.T., Disease severity in children and adults with Pompe disease related to age and disease duration. Neurology 64 (2005), 2139–2141.
7. Strothotte, S., Strigl-Pill, N., Grunert, B., et al. Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial. J Neurol 257 (2010), 91–97.
8. van der Ploeg, A.T., Clemens, P.R., Corzo, D., et al. A randomized study of alglucosidase alfa in late-onset Pompe's disease. N Engl J Med 362 (2010), 1396–1406.
9. Hagemans, M.L., Laforet, P., Hop, W.J., et al. Impact of late-onset Pompe disease on participation in daily life activities: evaluation of the Rotterdam Handicap Scale. Neuromuscul Disord 17 (2007), 537–543.
10. Merkies, I.S., Schmitz, P.I., van der Meche, F.G., Samijn, J.P., van Doorn, P.A., Psychometric evaluation of a new Handicap Scale in immune-mediated polyneuropathies. Muscle Nerve 25 (2002), 370–377.
11. Russell, D.J., Rosenbaum, P.L., Cadman, D.T., Gowland, C., Hardy, S., Jarvis, S., The gross motor function measure: a means to evaluate the effects of physical therapy. Dev Med Child Neurol 31 (1989), 341–352.
12. DeVellis, R.F., Classical test theory. Med Care 44 (2006), S50–S59.
13. Tesio, L., Functional assessment in rehabilitative medicine: principles and methods. Eura Medicophys 43 (2007), 515–523.
14. Rasch, G., Probabalistic models for some intelligence and attainment tests. 1993, MESA Press, Chicago.
15. Bond, T.G., Fox, C.M., Applying the Rasch model: fundamental measurement in the human sciences. 2001, Lawrence Erlbaum Associates, Mahwah.
16. Haley, S.M., Coster, W.J., Ludlow, L.H., et al. Pediatric evaluation of disability inventory (PEDI). Development, standardization and administration manual. 1992, New England Medical Center, Boston (MA).
17. World Health Organization, International classification of functioning, disability and health. 2001, WHO, Geneva.
18. Streiner, D.L., Norman, G.R., Health measurement scales. A practical guide to their development and use. 1998, Oxford University Press, New York.
19. Andrich, D., Sheridan, B., Luo, G., Rasch models for measurement: RUMM2030. 2010, RUMM Laboratory, Perth.
20. Hermans, M.C., Faber, C.G., de Baets, M.H., de Die-Smulders, C.E., Merkies, I.S., Rasch-built myotonic dystrophy type 1 activity and participation scale (DM1-Activ). Neuromuscul Disord 20 (2010), 310–318.
21. Tennant, A., Conaghan, P.G., The Rasch measurement model in rheumatology: what is it and why use it? When should it be applied, and what should one look for in a Rasch paper?. Arthritis Rheum 57 (2007), 1358–1362.
22. van Nes, S.I., Vanhoutte, E.K., van Doorn, P.A., et al. Rasch-built overall disability scale (R-ODS) for immune-mediated peripheral neuropathies. Neurology 76 (2011), 337–345.
23. Fischer, W.P., Reliability statistics. Rasch Meas Trans, 6, 1992, 238.
24. Dorans, N.J., Holland, P.W., DIF detection and description: mantel-Haenszel and standardisation. Holland, P.W., Wainer, H., (eds.) Differential item functioning, 1993, Lawrence Erlbaum Associates, Hillsdale, 33–36.
25. Embretson, S.E., Reise, S.P., Item response theory for psychologists. 2000, Lawrence Erlbaum Associates, New Yersey.
26. Linacre, J.M., Sample size and item calibration stability. Rasch Meas Trans, 7, 1994, 28.
27. Wright, B.D., Rack and stack: time 1 vs. time 2. Rasch Meas Trans 17 (2003), 905–906.
28. Medical Research Council, Aids to examination of the peripheral nervous system. Memorandum no. 45, 1st ed., 1976, Her Majesty's Stationary Office, London.
29. Herndon, J.E., Harrell, F.E., The restricted cubic spline hazard model. Commun Stat Theory Methods 19 (1990), 639–663.
30. Wright, B.D., Stone, M.H., Best test design: Rasch measurement. 1979, Mesa Press, Chicago.
31. Hobart, J.C., Cano, S.J., Thompson, A.J., Effect sizes can be misleading: is it time to change the way we measure change?. J Neurol Neurosurg Psychiatr 81 (2010), 1044–1048.
32. Lai, J.S., Eton, D.T., Clinically meaningful gaps. Rasch Meas Trans, 15, 2002, 850.
33. Hobart, J., Cano, S., Improving the evaluation of therapeutic interventions in multiple sclerosis: the role of new psychometric methods. Health Technol Assess 13 (2009), 1–200.
34. Bland, J.M., Altman, D.G., Multiple significance tests: the Bonferroni method. BMJ, 310, 1995, 170.
35. Merkies, I.S., Schmitz, P.I., van der Meche, F.G., Samijn, J.P., van Doorn, P.A., Connecting impairment, disability, and handicap in immune mediated polyneuropathies. J Neurol Neurosurg Psychiatr 74 (2003), 99–104.
36. Vandervelde, L., van den Bergh, P.Y., Goemans, N., Thonnard, J.L., ACTIVLIM: a Rasch-built measure of activity limitations in children and adults with neuromuscular disorders. Neuromuscul Disord 17 (2007), 459–469.
37. Haley, S.M., Fragala, M.A., Aseltine, R., Ni, P., Skrinar, A.M., Development of a disease-specific disability instrument for Pompe disease. Pediatr Rehabil 6 (2003), 77–84.
38. Jaeschke, R., Singer, J., Guyatt, G.H., Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials 10 (1989), 407–415.
39. Merkies, I.S., van Nes, S.I., Hanna, K., Hughes, R.A., Deng, C., Confirming the efficacy of intravenous immunoglobulin in CIDP through minimum clinically important differences: shifting from statistical significance to clinical relevance. J Neurol Neurosurg Psychiatr 81 (2010), 1194–1199.
40. Vanhoutte, E.K., Faber, C.G., van Nes, S.I., et al. Modifying the Medical Research Council grading system through Rasch analyses. Brain 135 (2012), 1639–1649.